1Bree RL, Arnold R J, Pettit KG, et al. Use of a dedcision-analytic model to support the use of a new oral US contrast agent in patients with abdominal pain. Acad Radiol, 2001, 8(3):234-242.
2Forsberg F, Goldberg BB, Liu JB, et al. Tissue-specific US contrast agent for evaluation of hepatic and splenic parenchyma,Radiology, 1999, 210(1): 125-132.
3El-Sherif DM, Wheatley MA. Development of a novel method for synthesis of a polymeric ultrasound contrast agent. J Biomed Mater Res A, 2003, 66(2): 347-355.
4Albrecht T, Hohmann J, Oldenburg A, et al.Detection and characterization of liver metastases. Eur Radiol, 2004, 14 (Suppl 8 ):25-33.
5Konopke R, Kersting S, Saeger HD, Detection of liver lesions by contrast-enhanced ultrasound-comparison to intraoperative findings. Ultraschall Med, 2005, 26(2): 107-113.
6Albrecht T, Blomley MJ, Cosgrove DO, el al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet, 1999, 354(9178) : 598-599.
7Lim AK, Taylor-Robinson SD, Patel N, et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut, 2005, 54 (1) : 128-133.
9Marshall MM, Beese RC, Muiesan P, et al.Assessment of portal venous system patency in the liver transplant candidate: a prospective study comparing ultrasound, microbubble-enhanced colour Doppler ultrasound, with arteriography and surgery, Clin Radiol,2002, 57(5): 377-383.
10Bruce M, Averkiou M, Tiemann K, et al. Vascular flow and perfusion imaging with ultrasound contrast agents. Ultrasound Med Biol,2004, 30(6): 735-743.
